COMMENTARY

LDP Heavyweights on Guard for Push to Scrap Coverage for Patch Medications

July 5, 2018
By Takashi Ohama Lawmakers of the ruling Liberal Democratic Party (LDP) have formed a study group to discuss issues surrounding patch medications. Despite its positioning as just a committee under another study group, its roster of executives is quite eye…

To read the full story

COMMENTARY

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…